基于“治未病”理论探讨中医药防治高血压前期
Exploring Traditional Chinese Medicine’s Approach to Prehypertension Management Based on the “Preventive Treatment for Disease” Theory
摘要: 随着现代生活节奏的加快和不良生活习惯的增加，高血压作为一种常见的慢性疾病，已成为全球范围内的重大健康问题。超过四分之一的人口被认为患有高血压，全球约13.9亿成年人(18岁以上)患有高血压，占成年人口的34%。高血压前期作为一种介于正常血压与高血压之间的状态，引起人们广泛关注。近年来，对高血压前期的研究进展主要集中在识别其作为心脑血管疾病风险因素的重要性，以及探索有效的预防和干预措施。本文旨在以治未病理念为基准，探讨中医药疗法防治高血压前期的研究进展，为预防和控制高血压前期提供参考。
Abstract: With the accelerated pace of modern life and the increase in poor lifestyle habits, hypertension, a common chronic disease, has become a major health problem worldwide. It is believed that more than a quarter of the population suffers from hypertension, and approximately 1.39 billion adults (18 years and older) worldwide, or 34% of the adult population, suffer from hypertension. Pre-hypertension has attracted much attention as a state between normal blood pressure and hypertension. In recent years, research advances in prehypertension have focused on determining its importance as a risk factor for cardiovascular and cerebrovascular diseases, as well as exploring effective preventive and intervention measures. The purpose of this paper is to explore the research progress of Chinese medicine in treating prehypertension from the concept of “preventive treatment for disease”, and to provide reference for the prevention and treatment of prehypertension.
文章引用：张知琳, 寇琳琳, 蒋析洋. 基于“治未病”理论探讨中医药防治高血压前期[J]. 中医学, 2025, 14(8): 3565-3571. https://doi.org/10.12677/tcm.2025.148524

参考文献

[1] Kario, K., Okura, A., Hoshide, S. and Mogi, M. (2024) The WHO Global Report 2023 on Hypertension Warning the Emerging Hypertension Burden in Globe and Its Treatment Strategy. Hypertension Research, 47, 1099-1102. [Google Scholar] [CrossRef] [PubMed]
[2] Han, M., Li, Q., Liu, L., Zhang, D., Ren, Y., Zhao, Y., et al. (2019) Prehypertension and Risk of Cardiovascular Diseases: A Meta-Analysis of 47 Cohort Studies. Journal of Hypertension, 37, 2325-2332. [Google Scholar] [CrossRef] [PubMed]
[3] Li, Z., Cao, L., Zhou, Z., Han, M. and Fu, C. (2023) Factors Influencing the Progression from Prehypertension to Hypertension among Chinese Middle-Aged and Older Adults: A 2-Year Longitudinal Study. BMC Public Health, 23, Article No. 339. [Google Scholar] [CrossRef] [PubMed]
[4] 刘明波, 何新叶, 杨晓红, 等. 《中国心血管健康与疾病报告2023》要点解读[J]. 中国心血管杂志, 2024, 29(4): 305-324.
[5] Malik, R., Georgakis, M.K., Vujkovic, M., Damrauer, S.M., Elliott, P., Karhunen, V., et al. (2021) Relationship between Blood Pressure and Incident Cardiovascular Disease: Linear and Nonlinear Mendelian Randomization Analyses. Hypertension, 77, 2004-2013. [Google Scholar] [CrossRef] [PubMed]
[6] Iring, A., Jin, Y., Albarrán-Juárez, J., Siragusa, M., Wang, S., Dancs, P.T., et al. (2019) Shear Stress-Induced Endothelial Adrenomedullin Signaling Regulates Vascular Tone and Blood Pressure. Journal of Clinical Investigation, 129, 2775-2791. [Google Scholar] [CrossRef] [PubMed]
[7] Hassan, D., Shakil Ur Rehman, S., Khalid, S., Tipu, I. and Husnain, M. (2024) Developing Lifestyle Intervention Program for Pre-Hypertensive Patients; Consensus Building Using a Modified Delphi Approach. PLOS ONE, 19, e0311766. [Google Scholar] [CrossRef] [PubMed]
[8] Fu, J., Liu, Y., Zhang, L., Zhou, L., Li, D., Quan, H., et al. (2020) Nonpharmacologic Interventions for Reducing Blood Pressure in Adults with Prehypertension to Established Hypertension. Journal of the American Heart Association, 9, e016804. [Google Scholar] [CrossRef] [PubMed]
[9] Park, S. (2019) Management Plans for Populations with Normal-To-Hypertensive Blood Pressures: Risks and Benefits of Antihypertensive Drug Treatment in Populations Previously Defined as Having High-Normal Blood Pressure. The Korean Journal of Internal Medicine, 34, 44-49. [Google Scholar] [CrossRef] [PubMed]
[10] 徐婧, 张立德, 程岩岩. 中医外治法防治高血压前期的临床研究进展[J]. 实用中医内科杂志, 2022, 36(1): 13-15.
[11] 何婧, 王艺霖, 陈丽娜. 观察中医体质辨识及干预在高血压前期“治未病”健康管理中的效果[J]. 中医临床研究, 2020, 12(3): 8-9.
[12] 李明昊, 侯承志, 艾克热木·艾尔肯, 等. 基于脉胀理论从营卫探讨无症状高血压病的辨治[J]. 环球中医药, 2024, 17(5): 824-826.
[13] 徐玉莲. 脉胀理论及益气化痰法治疗高血压的临床与实验研究[D]: [博士学位论文]. 广州: 广州中医药大学, 2017.
[14] 吴崇珊(Ng Chong Shan). 基于数据挖掘技术探讨高血压前期的中医证型、体质及用药规律[D]: [硕士学位论文]. 广州: 广州中医药大学, 2023.
[15] 刘振岳. 基于德尔菲法研究高血压前期的常见中医证候[J]. 内蒙古中医药, 2017, 36(8): 1.
[16] 郭梦阳, 邢冬梅, 王守富. 中医药在高血压前期防治中的应用综述[J]. 河南中医, 2023, 43(6): 957-961.
[17] 张维维, 吕燕, 郭敬, 等. 耳尖放血疗法的研究现状[J]. 中国中医基础医学杂志, 2024, 30(12): 2158-2160.
[18] 张翼祥, 周元淳, 李一钒, 等. 耳穴疗法治疗原发性高血压的研究进展[J]. 大医生, 2024, 9(5): 4-7.
[19] 胡旻, 赵广森, 程宁宁, 等. 耳穴贴压对不同体质高血压前期患者血压水平的影响[J]. 河南中医, 2024, 44(10): 1600-1605.
[20] 吴方萍, 吕素, 赵凯璐, 等. 耳部刮痧治疗失眠的研究进展[J/OL]. 中医学报: 1-9.
https://link.cnki.net/urlid/41.1411.R.20240912.1031.020, 2025-08-17.
[21] 林梅香, 黄丽华, 黄冬梅, 等. 耳部全息铜砭刮痧联合耳穴埋豆治疗社区肝阳上亢型高血压患者的应用效果分析[J]. 中外医疗, 2024, 43(20): 177-180.
[22] 原发性高血压病治未病干预指南[J]. 北京中医药大学学报, 2023, 46(8): 1063-1075.
[23] 魏肖禹, 王建波, 乔野, 等. 电针联合穴位贴敷对高血压前期大鼠肾脏AQP1、AQP2的影响[J]. 世界科学技术-中医药现代化, 2021, 23(11): 4351-4358.
[24] 黄国华, 李湘海, 陈小青. 内关、太冲穴位埋线对自发性高血压前期大鼠心肌AMPK信号通路的影响及意义[J]. 四川中医, 2024, 42(11): 56-60.
[25] 侯玮琼, 姜北, 赵岩, 等. 基于RhoA/ROCK通路研究天麻素对原发性高血压病左心室肥厚大鼠心室重塑的影响[J]. 安徽中医药大学学报, 2021, 40(1): 70-75.
[26] Giménez-Bastida, J.A., González-Sarrías, A., Vallejo, F., Espín, J.C. and Tomás-Barberán, F.A. (2016) Hesperetin and Its Sulfate and Glucuronide Metabolites Inhibit TNF-α Induced Human Aortic Endothelial Cell Migration and Decrease Plasminogen Activator Inhibitor-1 (PAI-1) Levels. Food & Function, 7, 118-126. [Google Scholar] [CrossRef] [PubMed]
[27] Li, M., Han, B., Zhao, H., Xu, C., Xu, D., Sieniawska, E., et al. (2022) Biological Active Ingredients of Astragali Radix and Its Mechanisms in Treating Cardiovascular and Cerebrovascular Diseases. Phytomedicine, 98, Article ID: 153918. [Google Scholar] [CrossRef] [PubMed]
[28] 周巍, 赵英强, 李甜, 等. 天麻钩藤饮对高血压前期大鼠血管内皮功能及miRNA表达影响的研究[J]. 山西中医, 2023, 39(8): 57-60.
[29] Zhang, H., Zhang, Q., Li, B., Li, L., Song, X., Xiong, C., et al. (2020) The Circulating Level of MIR-122 Is a Potential Risk Factor for Endothelial Dysfunction in Young Patients with Essential Hypertension. Hypertension Research, 43, 511-517. [Google Scholar] [CrossRef] [PubMed]
[30] 张云雨, 曲怡, 王建波, 等. 基于TXNIP/GSDMD通路探讨补阳还五汤抑制原发性高血压病大鼠内皮焦亡作用机制[J]. 辽宁中医药大学学报, 2024, 26(6): 19-24.
[31] 薛亚楠, 张立德, 王建波, 等. 补阳还五汤调节血管内皮细胞炎症信号通路干预高血压前期血管损伤机制[J]. 科学技术与工程, 2022, 22(25): 10906-10911.
[32] 徐男, 王亮, 时海燕, 等. 基于整合药理学平台探究半夏白术天麻汤治疗高血压的分子机制[J]. 中国实验方剂学杂志, 2019, 25(2): 109-117.